DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants

Information source: Janssen Pharmaceutical K.K.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Healthy

Intervention: TMC278 (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Janssen Pharmaceutical K.K.

Official(s) and/or principal investigator(s):
Janssen Pharmaceutical K.K., Japan Clinical Trial, Study Director, Affiliation: Janssen Pharmaceutical K.K.

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of TMC278 after a single oral dose of TMC278 25 mg tablet (27. 5 mg as the hydrochloride salt) under fed conditions in healthy Japanese adult male participants.

Clinical Details

Official title: An Open-label, Single-dose Study to Investigate the Pharmacokinetics and Safety of TMC278 After Oral Administration of TMC278 25 mg Tablet Under Fed Condition in Healthy Japanese Adult Male Subjects

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: plasma TMC278 concentrations

Secondary outcome: The number of participants who experience adverse events

Detailed description: This is a single center, open-label (all study staff and participants will know the identity of the treatment assigned), single dose study in healthy Japanese adult male participants. The study consists of 3 phases: a screening phase up to 26 days; an inpatient phase from Day

- 2 to Day 8; and a follow-up assessment phase that occurs on Day 15 (± 2 days) or at the

time of the participant's early withdrawal from the study. Participants who meet the selection criteria will be admitted to the investigational institute on two days before the

dose (Day - 2). All enrolled participants will receive orally (by mouth) a single dose of one

TMC278 25 mg tablet on Day 1 within 10 minutes after completion of the standardized breakfast. Enrolled participants will remain in the investigational institute for the entire duration of the inpatient phase. Participants will be discharged on Day 8 after the completion of all required assessments. Blood samples for determination of plasma concentrations of TMC278 will be collected over a period of 168 hours (7 days). The maximum study duration for each participant is 45 days, including the screening phase, in-patient period, and follow-up visit.

Eligibility

Minimum age: 20 Years. Maximum age: 40 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Japanese healthy men

- body mass index (BMI) between 18. 5 and 25. 0 kg/m², inclusive and a body weight of not

less than 50 kg Exclusion Criteria:

- History of or current medical illness considered by the investigator to be clinically

significant and should exclude the participant or that could interfere with the interpretation of the study results

- Laboratory abnormality of grade 2 or greater (defined by the World Health

Organization Adult Toxicity Table) or clinically significant abnormal values as assessed by the investigators

- Clinically significant abnormal physical examination and vital signs at screening as

assessed by the investigators

- Use of any prescription or nonprescription medication (including vitamins and herbal

supplements), within 14 days before the dose of TMC278 25 mg tablet

- History of clinically significant drug or food allergies, especially known

hypersensitivity and/or known allergy to TMC278 or any of the excipients of the formulation

Locations and Contacts

Tokyo, Japan
Additional Information

An Open-label, Single-dose Study to Investigate the Pharmacokinetics and Safety of TMC278 after Oral Administration of TMC278 25 mg Tablet under Fed Condition in Healthy Japanese Adult Male Subjects

Starting date: March 2013
Last updated: March 18, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017